* Development of the efficiency frontier approach was necessary to meet legal requirements, but ongoing health care reforms and changing objectives have altered the landscape.
* Current drug price negotiations depend on early benefit assessments from pharmaceutical companies, raising questions about the SHI system’s sustainability and its need to utilize health economic evaluations for various interventions.